We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials.
- Authors
Montefiori, David C; Karnasuta, Chitraporn; Huang, Ying; Ahmed, Hasan; Gilbert, Peter; de Souza, Mark S; McLinden, Robert; Tovanabutra, Sodsai; Laurence-Chenine, Agnes; Sanders-Buell, Eric; Moody, M Anthony; Bonsignori, Mattia; Ochsenbauer, Christina; Kappes, John; Tang, Haili; Greene, Kelli; Gao, Hongmei; LaBranche, Celia C; Andrews, Charla; Polonis, Victoria R; Rerks-Ngarm, Supachai; Pitisuttithum, Punnee; Nitayaphan, Sorachai; Kaewkungwal, Jaranit; Self, Steve G; Berman, Phillip W; Francis, Donald; Sinangil, Faruk; Lee, Carter; Tartaglia, Jim; Robb, Merlin L; Haynes, Barton F; Michael, Nelson L; Kim, Jerome H
- Abstract
A recombinant canarypox vector expressing human immunodeficiency virus type 1 (HIV-1) Gag, Pro, and membrane-linked gp120 (vCP1521), combined with a bivalent gp120 protein boost (AIDSVAX B/E), provided modest protection against HIV-1 infection in a community-based population in Thailand (RV144 trial). No protection was observed in Thai injection drug users who received AIDSVAX B/E alone (Vax003 trial). We compared the neutralizing antibody response in these 2 trials.
- Publication
The Journal of infectious diseases, 2012, Vol 206, Issue 3, p431
- ISSN
1537-6613
- Publication type
Journal Article
- DOI
10.1093/infdis/jis367